Ionis Pharmaceuticals, Inc. filings document an operating biotechnology company focused on RNA-targeted medicines, marketed products, partnered programs, and clinical-stage pipeline assets. Form 8-K reports cover GAAP and non-GAAP financial results, product-sales updates, Regulation FD disclosures, clinical data releases, and regulatory communications involving programs such as zilganersen in Alexander disease and bepirovirsen in chronic hepatitis B.
Proxy materials describe annual meeting procedures, director matters, board governance, and stockholder voting items. Other filings record capital-structure events and material agreements, including the completed private offering of convertible senior notes due 2030, along with exhibit filings and related corporate disclosures.
Insider transactions by Patrick R. O'Neil, EVP, CLO & General Counsel of Ionis Pharmaceuticals (IONS): The Form 4 reports multiple transactions dated 09/09/2025 showing both acquisitions and dispositions of Ionis common stock and related options. The reporting person acquired 21,000 shares (20,000 and 1,000) via option-related transactions at exercise prices shown and sold 21,000 shares under a Rule 10b5-1 trading plan at a weighted average sale price of $64.5553 per share. Following the reported activity the filer beneficially owns between 57,130 and 77,203 shares depending on the line item.
The filing discloses that the sales were made pursuant to a 10b5-1 plan adopted May 2, 2025, and that the reported sale price is a weighted average reflecting multiple executions between $64.50 and $64.66. The filer offers to provide detailed per-trade prices on request.
Joseph T. Baroldi, EVP and Chief Business Officer of Ionis Pharmaceuticals (IONS), reported multiple Section 16 transactions on 09/05/2025 under a previously adopted Rule 10b5-1 plan. He exercised 250 non-qualified stock options with a $31.80 exercise price and immediately acquired 250 shares. Simultaneously, he sold 250 shares pursuant to his 10b5-1 plan at an average price of $62, leaving him with 31,926 shares directly and 3,071 shares indirectly held by his spouse. After the option exercise, total direct beneficial ownership of common stock reported is 53,650 shares.
The filing discloses the trades were executed pursuant to a 10b5-1 trading plan adopted May 2, 2025, and the Form 4 was signed by an attorney-in-fact on 09/09/2025. No other compensatory or material corporate events are disclosed in this Form 4.
Insider sale recorded on Form 4: Ionis Pharmaceuticals EVP and Chief Scientific Officer C. Frank Bennett sold 6,000 shares of Ionis common stock on 09/05/2025 at a weighted average price of $59.5968 per share, reducing his beneficial ownership to 82,679 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted May 13, 2025, and occurred in multiple transactions at prices ranging from $59.25 to $59.86. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/09/2025.
Eric Swayze, EVP Research at Ionis Pharmaceuticals (IONS), reported insider sales on 09/02/2025. He sold 10,000 shares at a weighted average price of $49.22 and 1,130 shares at a weighted average price of $53.6829 under a Rule 10b5-1 trading plan adopted August 14, 2024. After these transactions the filing shows beneficial ownership figures of 38,432 and 37,302 shares respectively, and an indirect holding of 184 shares held by his son. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Joseph H. Wender, a director of Ionis Pharmaceuticals, Inc. (IONS), reported multiple sales under a Rule 10b5-1 trading plan adopted December 16, 2024. On 09/02/2025 he reported disposing of 11,200 shares at a weighted-average price of $55.0386 (sales priced between $55.000 and $55.180) and disposing of 5,600 shares at a weighted-average price of $57.5311 (prices between $57.500 and $57.575), leaving his beneficial ownership at 120,035 shares after that transaction. On 09/03/2025 he reported disposing of 11,200 shares at a weighted-average price of $60.1383 (prices between $60.00 and $60.53), leaving his beneficial ownership at 108,835 shares. The Form 4 was signed by Patrick R. O'Neil as attorney-in-fact for Mr. Wender on 09/04/2025.
Insider sale reported by Director B. Lynne Parshall of Ionis Pharmaceuticals (IONS). On 09/02/2025 the reporting person sold a total of 20,000 shares of Ionis common stock in two transactions executed under a Rule 10b5-1 trading plan adopted May 6, 2025. The first block of 10,750 shares was sold at a weighted-average price of $50.42 (individual trades ranged $50.0137–$50.92) leaving 75,594 shares beneficially owned after the sale. The second block of 9,250 shares was sold at a weighted-average price of $51.49 (individual trades ranged $51.24–$51.81) leaving 66,344 shares beneficially owned after that sale. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals (IONS), reported multiple transactions on 09/03/2025 that offset each other, resulting in no net change to total common shares held. On that date the reporting person acquired 203,814 shares through exercises and market purchases and sold 203,814 shares under a Rule 10b5-1 trading plan adopted August 13, 2024. The filings show weighted-average sale prices in three ranges: $58.57–$59.55, $59.60–$60.57, and $60.61–$61.48. Following the transactions the reporting person beneficially owned 180,009 common shares. The Form 4 also lists exercises of non-qualified stock options at strike prices of $32.60, $37.58, and $53.77, with resulting increases in underlying common shares reported in Table II.
Joseph Klein III, a director of Ionis Pharmaceuticals, reported multiple transactions dated 09/03/2025. The filing shows two non-derivative acquisitions recorded as 16,000 and 12,000 shares of common stock reported with transaction code M and price listed as $0.0, each noted as indirectly owned by a trust. On the same date the form records a sale of 28,000 common shares at $60 per share, with an explanatory note stating the sale was made pursuant to a Rule 10b5-1 trading plan adopted January 3, 2024. The report also lists 16,346 shares held directly and 100 shares held indirectly by his son, with the filer disclaiming beneficial ownership of the son's shares.
Joseph Klein III, a director of Ionis Pharmaceuticals, reported multiple transactions on 09/03/2025. The filing shows option exercises resulting in receipt of common stock and contemporaneous sales executed under a Rule 10b5-1 trading plan. Specifically, the report lists exercises of options that generated 12,000 and 16,000 shares credited to a trust, and a sale of 28,000 shares at $60 per share pursuant to the 10b5-1 plan. The filing also reports a disposition of 16,346 shares and notes 100 shares held by his son for which he disclaims beneficial ownership. All transactions are reported as indirect holdings through a trust except the 100 shares held by his son.
Richard S. Geary, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals (IONS), reported the sale of 10,000 shares of common stock on 09/02/2025. The shares were sold at a weighted average price of $50.3671 per share (individual trades ranged from $50.01 to $50.92). After the reported disposition, Mr. Geary beneficially owns 79,657 shares. The filing states the sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2025, and the filer offers to provide trade-level detail on request.